Aspirin, enoxaparin for VTE prophylaxis yield similar 90-day mortality rates after TJA
Click Here to Manage Email Alerts
Key takeaways:
- Patients who received either aspirin or enoxaparin for venous thromboembolism prophylaxis had similar mortality rates.
- Researchers deemed enoxaparin to be noninferior to aspirin for these patients.
Investigators of this study found similar 90-day mortality rates for patients who underwent total joint arthroplasty with either aspirin or enoxaparin for venous thromboembolism prophylaxis.
Verinder S. Sidhu, MS, and colleagues performed a secondary analysis of the CRISTAL cluster randomized trial to analyze 90-day mortality rates among 14,156 patients who received aspirin and 9,302 patients who received enoxaparin for venous thromboembolism (VTE) prophylaxis during total hip or total knee arthroplasty. According to the study, patients received either 100 mg of oral aspirin daily or 40 mg of subcutaneous enoxaparin daily for 35 days after THA and 14 days after TKA.
Overall, 90-day mortality was 1.67% in the aspirin group and 1.53% in the enoxaparin group. Subgroup analysis of 21,148 patients without a fracture diagnosis found a 0.49% mortality rate in the aspirin group and 0.41% mortality rate in the enoxaparin group at 90 days. Researchers deemed these differences not statistically significant, according to the study.
“In conjunction with the results from the primary CRISTAL study, these findings suggest that enoxaparin reduces the risk of symptomatic VTE without increasing the risk of mortality in comparison to aspirin after hip or knee arthroplasty,” Sidhu and colleagues wrote in the study.
Collapse
Click Here to Manage Email Alerts